Merck's Remigromig Meets Non-Inferiority Goal in DME Trial

Merck's investigational drug remigromig has met the primary endpoint in a pivotal Phase 2b/3 trial for diabetic macular edema, demonstrating non-inferiority to ranibizumab.

The BRUNELLO trial enrolled 984 patients with diabetic macular edema who received either 0.5 mg or 0.8 mg doses of remigromig or 0.5 mg ranibizumab every four weeks.

At 52 weeks, both doses of remigromig independently demonstrated non-inferiority to ranibizumab for mean change from baseline in best-corrected visual acuity.

Remigromig is a tetravalent, tri-specific antibody designed to activate the Wnt pathway, which is involved in the repair and maintenance of the blood-retinal barrier.